Association between phospholipids and free cholesterol in high-density lipoprotein and the response to hepatitis C treatment in Japanese with genotype 1b

Journal of Viral Hepatitis

Volumn 17, Issue 12, 2010, Pages 859-865

  Mawatari, H ^a   Yoneda, M ^a   Fujita, K ^a   Nozaki, Y ^a   Shinohara, Y ^a   Sasaki, H ^b   Iida, H ^a   Takahashi, H ^a   Inamori, M ^a   Abe, Y ^a   Kobayashi, N ^a   Kubota, K ^a   Kirikoshi, H ^a   Nakajima, A ^a   Saito, S ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Skylight Biotech Inc   (Japan)

Author keywords

free cholesterol; hepatitis C virus; high performance liquid chromatography; interferon; nonvirological responses; phospholipid

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; PEGINTERFERON ALPHA2B; PHOSPHOLIPID; RIBAVIRIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GEL PERMEATION CHROMATOGRAPHY; GENOTYPE; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPANESE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PARTICLE SIZE; PHOSPHOLIPID BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTIVIRAL AGENTS; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; JAPAN; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 78649243456     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01253.x     Document Type: Article

References (42)

1. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH,. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132 (4): 296 - 305.
2. Seeff LB, Hoofnagle JH, National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36 (5 Suppl. 1): S1 - S2.
3. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990; 87 (17): 6547 - 6549.
4. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328 (25): 1797 - 1801. (Pubitemid 23174709)
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347 (13): 975 - 982.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958 - 965.
7. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L,. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997; 157 (7): 792 - 796.
8. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M,. Blood lipids of patients with chronic hepatitis: differences related to viral etiology. Clin Chim Acta 1997; 261 (2): 159 - 165.
9. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R,. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34 (3): 428 - 434.
10. Mawatari H, Yoneda M, Fujita K, et al. Association between lipoprotein subfraction profile and the response to hepatitis C treatment in Japanese patients with genotype 1b. J Viral Hepat 2009; August 25 [Epub ahead of print].
11. Hara I, Okazaki M,. High-performance liquid chromatography of serum lipoproteins. Methods Enzymol 1986; 129: 57 - 78.
12. Okazaki M, Usui S, Ishigami M, et al. Identification of unique lipoprotein subclasses for visceral obesity by component analysis of cholesterol profile in high-performance liquid chromatography. Arterioscler Thromb Vasc Biol 2005; 25 (3): 578 - 584.
13. Usui S, Hara Y, Hosaki S, Okazaki M,. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002; 43 (5): 805 - 814.
14. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ,. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19 (6): 1513 - 1520.
15. Hu W, Abe-Dohmae S, Tsujita M, et al. Biogenesis of HDL by SAA is dependent on ABCA1 in the liver in vivo. J Lipid Res 2008; 49 (2): 386 - 393.
16. Hsu M, Zhang J, Flint M, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003; 100 (12): 7271 - 7276.
17. Drummer HE, Maerz A, Poumbourios P, Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett 2003; 546 (2-3): 385 - 390.
18. Bartosch B, Dubuisson J, Cosset FL,. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197 (5): 633 - 642.
19. Bartosch B, Verney G, Dreux M, et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 2005; 79 (13): 8217 - 8229.
20. Catanese MT, Graziani R, Von Hahn T, et al. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol 2007; 81 (15): 8063 - 8071.
21. Dreux M, Pietschmann T, Granier C, et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 2006; 281 (27): 18285 - 18295.
22. Meunier JC, Engle RE, Faulk K, et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 2005; 102 (12): 4560 - 4565.
23. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N,. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005; 280 (9): 7793 - 7799.
24. Dreux M, Boson B, Ricard-Blum S, et al. The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. J Biol Chem 2007; 282 (44): 32357 - 32369.
25. Meunier JC, Russell RS, Engle RE, Faulk KN, Purcell RH, Emerson SU,. Apolipoprotein c1 association with hepatitis C virus. J Virol 2008; 82 (19): 9647 - 9656.
26. Chang KS, Jiang J, Cai Z, Luo G,. Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol 2007; 81 (24): 13783 - 13793.
27. Ji Y, Jian B, Wang N, et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997; 272 (34): 20982 - 20985.
28. Liadaki KN, Liu T, Xu S, et al. Binding of high density lipoprotein (HDL) and discoidal reconstituted HDL to the HDL receptor scavenger receptor class B type I. Effect of lipid association and APOA-I mutations on receptor binding. J Biol Chem 2000; 275 (28): 21262 - 21271.
29. Simons K, Ikonen E,. How cells handle cholesterol. Science 2000; 290 (5497): 1721 - 1726.
30. Sheridan DA, Price DA, Schmid ML, et al. Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin. Aliment Pharmacol Ther 2009; 29 (12): 1282 - 1290.
31. D'Arondel C, Munteanu M, Moussalli J, et al. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. J Viral Hepat 2006; 13 (3): 182 - 189.
32. Gopal K, Johnson TC, Gopal S, et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 2006; 44 (2): 335 - 340.
33. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46 (3): 403 - 410.
34. Krieger M,. Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems. J Clin Invest 2001; 108 (6): 793 - 797.
35. Acton SL, Scherer PE, Lodish HF, Krieger M,. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem 1994; 269 (33): 21003 - 21009.
36. Xu S, Laccotripe M, Huang X, Rigotti A, Zannis VI, Krieger M,. Apolipoproteins of HDL can directly mediate binding to the scavenger receptor SR-BI, an HDL receptor that mediates selective lipid uptake. J Lipid Res 1997; 38 (7): 1289 - 1298.
37. Chernomordik LV, Kozlov MM,. Protein-lipid interplay in fusion and fission of biological membranes. Annu Rev Biochem 2003; 72: 175 - 207.
38. Parathath S, Connelly MA, Rieger RA, et al. Changes in plasma membrane properties and phosphatidylcholine subspecies of insect Sf9 cells due to expression of scavenger receptor class B, type I, and CD36. J Biol Chem 2004; 279 (40): 41310 - 41318.
39. Kellner-Weibel G, De La Llera-Moya M, Connelly MA, et al. Expression of scavenger receptor BI in COS-7 cells alters cholesterol content and distribution. Biochemistry 2000; 39 (1): 221 - 229.
40. De La Llera-Moya M, Rothblat GH, Connelly MA, et al. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res 1999; 40 (3): 575 - 580.
41. Umashankar M, Sanchez-San Martin C, Liao M, et al. Differential cholesterol binding by class II fusion proteins determines membrane fusion properties. J Virol 2008; 82 (18): 9245 - 9253.
42. Rawat SS, Viard M, Gallo SA, Rein A, Blumenthal R, Puri A,. Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review). Mol Membr Biol 2003; 20 (3): 243 - 254.